18F-FDG PET as a predictor of pulmonary function in sarcoidosis

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 28, Issue 2, 2011, Pages 123-129

  Keijsers, Ruth G ^a   Verzijlbergen, F J ^a   Van Den Bosch, J M ^a   Zanen, P ^a   Van De Garde, E M ^a   Oyen, W J ^b   Grutters, J C ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

18F FDG PET; Pulmonary function tests; Sarcoidosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE ACTIVITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MALE; METABOLISM; PARENCHYMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SARCOIDOSIS; VITAL CAPACITY; ANALYSIS OF VARIANCE; CHI SQUARE DISTRIBUTION; HOSPITALIZATION; LUNG; LUNG FUNCTION TEST; MIDDLE AGED; NETHERLANDS; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; SCINTISCANNING; TIME;

ADULT; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; FEMALE; FLUORODEOXYGLUCOSE F18; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; MIDDLE AGED; NETHERLANDS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULMONARY DIFFUSING CAPACITY; RADIOPHARMACEUTICALS; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SARCOIDOSIS, PULMONARY; SEVERITY OF ILLNESS INDEX; TIME FACTORS; VITAL CAPACITY;

EID: 81455142049     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), me European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160 (2): 736-55.
2. Lynch JP, III, Ma YL, Koss MN, White ES. Pulmonary sarcoidosis. Semin Respir Crit Care Med 2007; 28 (1): 53-74. (Pubitemid 46364272)
3. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation. Br Med J 1961; 2 (5261): 1165-72.
4. Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. QJ Med 1983; 52 (208): 525-33. (Pubitemid 14245588)
5. Boros PW, Enright PL, Quanjer PH, Borsboom GJ, Wesolowski SP, Hyatt RE. Impaired lung compliance and DLCO but no restrictive ventilatory defect in sarcoidosis. Eur Respir J 2010.
6. Winterbauer RH, Hutchinson JF. Use of pulmonary function tests in the management of sarcoidosis. Chest 1980; 78 (4): 640-7. (Pubitemid 10005888)
7. Braun JJ, Kessler R, Constantinesco A, Imperiale A. (18)F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging 2008; 35 (8): 1537-43.
8. Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007; 132 (6): 1949-53.
9. Yamada Y, Uchida Y, Tatsumi K et al. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J Nucl Med 1998; 39 (7): 1160-6. (Pubitemid 28326144)
10. Kruit A, Gratters JC, Gerritsen WB, et al. ACE I/D-corrected Z-scores to identify normal and elevated ACE activity in sarcoidosis. Respir Med 2007; 101 (3): 510-5. (Pubitemid 46196325)
11. MacIntyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005; 26 (4): 720-35. (Pubitemid 41448672)
12. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26 (2): 319-38. (Pubitemid 41079078)
13. Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. Eur Respir J 2005; 26 (1): 153-61. (Pubitemid 40945944)
14. Boellaard R, Oyen WJ, Hoekstra CJ, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 2008; 35 (12): 2320-33.
15. De Vries J, Drent M. Quality of life and health status in sarcoidosis: a review. Semin Respir Crit Care Med 2007; 28 (1): 121-7. (Pubitemid 46364276)
16. Ainslie GM, Benatar SR. Serum angiotensin converting enzyme in sarcoidosis: sensitivity and specificity in diagnosis: correlations with disease activity, duration, extra-thoracic involvement, radiographic type and therapy. QJ Med 1985; 55 (218): 253-70. (Pubitemid 15028241)
17. Keicho N, Kitamura K, Takaku F, Yotsumoto H. Serum concentration of soluble interleukin-2 receptor as a sensitive parameter of disease activity in sarcoidosis. Chest 1990; 98 (5): 1125-9. (Pubitemid 20381274)
18. Keijsers RG, Verzijlbergen FJ, Oyen WJ, et al. 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. Eur J Nucl Med Mol Imaging 2009; 36 (7): 1131-7.